LifeMD Earnings Call: Growth Surges, Profits Deferred

Lifemd, Inc. ((LFMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

LifeMD’s latest earnings call painted a cautiously optimistic picture, as management highlighted record subscriber growth, expanding gross margins, and strong momentum in weight management and Women’s Health while acknowledging pressure on near-term profitability. Executives framed the quarter as an investment phase, marked by heavy marketing spend, a shift toward branded drugs, and negative adjusted EBITDA, but stressed confidence in a second-half earnings inflection.

Revenue Beat and Reaffirmed Full-Year Targets

LifeMD reported Q1 revenue of $50.2 million, modestly above its guidance range of $48 million to $49 million, signaling solid top-line execution despite a challenging product transition. Management reaffirmed full-year 2026 revenue guidance of $220 million to $230 million, implying 13% to 19% growth and an annualized revenue run-rate of more than $250 million by the fourth quarter.

Subscriber Growth Hits Record Levels

The company delivered the largest quarterly net addition in its history, adding roughly 42,000 telehealth subscribers in Q1 and ending the period with more than 365,000 active subscribers. That base represents about 26% year-over-year growth, underscoring LifeMD’s ability to attract and retain patients across its virtual care platform even as it refines its product mix and pricing.

Weight Management Drives New Patient Momentum

Weight management remained the key growth engine, with sign-ups surging approximately 120% sequentially from Q4 and total weight management patients approaching 100,000. Importantly for investors focused on efficiency, customer acquisition costs improved by about 4% to 5% quarter-over-quarter even as daily new patient volumes roughly doubled from around 300 to 400 per day to as high as 600 to 1,000.

Women’s Health Shows Rapid Early Traction

Women’s Health emerged as a promising new pillar, with subscribers growing more than sevenfold from the Q4 base as LifeMD leaned into hormone and bone-health solutions. On-therapy retention is already tracking above 80%, and management plans to introduce seven new compounded pharmacy products to deepen this category and support longer-term recurring revenue.

RexMD Expands Across Categories

RexMD, LifeMD’s men’s health brand, now serves about 215,000 active patients, with growth spread across erectile dysfunction, sleep, and hair loss offerings. Sleep is the fastest-growing segment, while personalized erectile dysfunction medications combining sildenafil and tadalafil grew more than 40% versus Q4, and in-house fulfillment is expected to further expand margins in this portfolio.

Gross Margins Climb Despite Flat Sales

Even with Q1 revenue essentially flat year-over-year at $50.2 million versus $50.9 million, LifeMD expanded gross margin by roughly 420 basis points to 88%, driving gross profit to $44.2 million, up about 3%. Management credited lower shipping and fulfillment costs and scale benefits in its in-house pharmacy, signaling improving unit economics beneath the surface of the topline.

Pharmacy Scale and Insurance Coverage Build Moat

The affiliated pharmacy now operates a 22,500-square-foot facility licensed in all 50 states, processing about 20,000 prescriptions per month with capacity to grow. Covered lives have expanded from roughly 112 million at quarter end to an expected 230 million by month-end, positioning LifeMD to leverage broader insurance-supported access, including a Medicare GLP-1 bridge program set to launch in July.

Solid Liquidity and Balance Sheet Flexibility

LifeMD ended Q1 with $34.5 million in cash, no debt, and a $30 million undrawn revolving credit facility, providing ample runway to fund its growth and technology initiatives. This balance sheet strength offers a cushion as the company navigates higher marketing spend, a product-mix transition, and continued investment in AI and operations before EBITDA turns sustainably positive.

AI Strategy Aims to Unlock Operating Leverage

Management is aggressively rolling out AI tools across intake, clinical documentation, decision support, revenue cycle management, and back-office workflows to boost provider capacity and reduce manual overhead. The company expects the margin benefits from these deployments to become more visible in 2026, suggesting a medium-term catalyst for operating leverage as volumes scale on the telehealth platform.

Product Mix Shift Weighs on Near-Term Revenue

While overall revenue was stable year-over-year, the shift from compounded GLP-1s to branded drugs reduced near-term revenue per unit and masked underlying patient growth. Management acknowledged that unit economics for some branded therapies are currently softer than the prior compounded offerings but argued that scale and deeper insurance integration should eventually normalize profitability.

GAAP Loss Widens and Adjusted EBITDA Turns Negative

The company posted a GAAP net loss from continuing operations of $9.6 million, or $0.20 per diluted share, versus a $2.4 million loss a year ago, reflecting heavier operating investments. Adjusted EBITDA deteriorated to a loss of about $4.5 million from positive $3.7 million in the prior-year period, landing in line with guidance but underscoring the earnings drag from front-loaded growth spending.

Marketing Surge Temporarily Pressures Profitability

Selling and marketing expenses jumped around 34% year-over-year to $29.8 million, as LifeMD executed a strategic, front-loaded push to acquire patients, particularly in weight management and Women’s Health. Management emphasized that Q1 represents peak marketing investment, with spend expected to step down to about $26 million to $27 million in Q2 and a lower combined level across the second half.

Short-Term Guidance Signals Possible Q2 Soft Patch

LifeMD guided Q2 revenue to a range of $47 million to $50 million, implying potential sequential softness relative to Q1’s $50.2 million as the company optimizes revenue cycle management and navigates the mix shift. Q2 adjusted EBITDA is projected between a $2 million loss and a $1 million profit, reflecting ongoing operating tweaks, cross-sell improvements, and insurance integrations still being refined.

Forward-Looking Outlook Points to H2 Inflection

Management reaffirmed full-year revenue guidance of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million, with a target of surpassing a $250 million annualized revenue run-rate and $25 million-plus annualized adjusted EBITDA by Q4. Leadership expects a return to adjusted EBITDA profitability in the second half, driven by expanding insurance coverage, improving pharmacy economics, cross-selling gains, AI-driven efficiency, and normalized marketing levels.

LifeMD’s earnings call portrayed a business in transition, trading near-term margin softness for accelerated subscriber growth and category expansion in key areas like weight management and Women’s Health. For investors, the story now hinges on whether the company can translate its growing scale, pharmacy footprint, and AI initiatives into the EBITDA ramp and more durable profitability promised for the back half of the year and beyond.